Halper Sadeh LLC Launches Investigations on NVEE, CARM, HLGN for Shareholder Rights

Shareholder Investigation into NVEE, CARM, and HLGN by Halper Sadeh LLC

In a significant move to safeguard investor rights, Halper Sadeh LLC, a leading law firm specializing in investor protection, has announced that it is launching inquiries into several companies, including NV5 Global, Inc. (NASDAQ: NVEE), Carisma Therapeutics Inc. (NASDAQ: CARM), and Heliogen, Inc. (OTCQX: HLGN). These investigations are aimed at identifying any potential breaches of federal securities laws or fiduciary duties owed to shareholders by these companies.

NV5 Global, Inc.

The focus of the investigation into NV5 Global centers on its proposed sale to Acuren Corporation, a transaction that could impact shareholders significantly. If the deal goes through, NV5 shareholders are set to receive approximately $23.00 per share, comprising $10.00 in cash and an estimated $13.00 in Acuren common stock. Given the substantial amounts involved, it's vital for shareholders to be informed about their rights in this transaction. Halper Sadeh LLC is actively reaching out to NV5 shareholders to discuss their options and rights within this context.

Carisma Therapeutics Inc.

In addition, the firm is probing Carisma Therapeutics regarding its merger with OrthoCellix, Inc. Following the completion of this merger, Carisma's existing shareholders are anticipated to hold about 10% of the merged entity. This substantial dilution of ownership raises questions about the fairness and appropriateness of the merger terms for shareholders. Halper Sadeh LLC welcomes existing Carisma shareholders to come forward to understand their legal rights amid these developments.

Heliogen, Inc.

The sale of Heliogen to Zeo Energy Corp. is also under scrutiny. According to the terms, Heliogen's security holders are expected to receive shares of Zeo’s Class A common stock, with the whole package valued around $10 million, contingent upon Heliogen's net cash at closing. The legal implications of this sale are critical for Heliogen’s shareholders, who need to be fully aware of their rights and the ramifications of the deal.

Legal Support for Investors

Halper Sadeh LLC is dedicated to advocating on behalf of shareholders who might feel disadvantaged by these corporate actions. The firm's approach often includes seeking increased compensation for shareholders, additional disclosures, or other forms of relief to ensure that investor interests are adequately protected. The law firm operates on a contingency fee arrangement, implying that shareholders won’t have to pay legal fees out of their pockets unless the case results in a financial recovery.

As part of its commitment to supporting investors, Halper Sadeh LLC invites shareholders from NV5 Global, Carisma Therapeutics, and Heliogen to consult with the firm without any financial obligation. Investors who wish to raise their concerns or inquiries can reach out directly to attorneys Daniel Sadeh or Zachary Halper via phone at (212) 763-0060 or through email.

Conclusion

Halper Sadeh LLC's move to investigate these transactions reflects a broader trend in the corporate landscape where shareholder advocacy plays a crucial role. As the marketplace continues to evolve, the rights and interests of investors need to be accessible and well represented. With millions at stake, ongoing legal guidance is pivotal for shareholders navigating these complex landscapes. Investors are urged to act promptly to protect their rights and ensure they understand the implications of these corporate maneuvers.